Cure My Disease

Don't miss your cure!

 Log in / Sign up

Scientists probe link between stress hormone and 'Bliss Molecule' in rare disease

NCT ID NCT02889224

Knowledge-focused Sponsor: University Hospital, Bordeaux Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at how the body's natural endocannabinoids (similar to cannabis compounds) interact with the stress hormone cortisol in people with Cushing's syndrome, a condition of high cortisol. Researchers measured blood levels of these compounds in 40 participants, including those with Cushing's, obesity, and healthy controls. The goal was to understand if cortisol drives changes in endocannabinoids, which could help explain symptoms of Cushing's.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could reveal how the body's natural cannabinoid system responds to cortisol, pointing toward new ways to understand or manage Cushing's syndrome.
What could go wrong
This is a small, early-stage observational study with only 40 participants. It is designed to gather knowledge, not to test a treatment, so it may not lead directly to any therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

40 people

The number who actually took part.

Start date

Feb 2012

Finished

Sep 2013

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: For all patients groups: * Age ≥ 18, * Social security. " Hypercortisolism " group: * 18 \< BMI \< 40 kg/m2, * Cushing's syndrome in front of : * impaired 1 mg dexamethasone test (08:00 A.M. cortisol \> 50 nmol/L) * qualitative and quantitative disrupted circadian rhythm of cortisol with increased plasma concentrations * free urinary cortisol upper normal range (90 µg/24H), * Hypercortisolism that can be treated with surgery (adrenal adenoma treated with adrenalectomy or Cushing disease treated with pituitary surgery). " Obese " group: * Obese patients: 30 \< BMI \< 40 kg/m2, * Normal HPA axis function: * 08:00 A.M. cortisol \> 250 nmol/L and peak above 550 nmol/L after 1 mg SST, * Normal 24H free urinary cortisol and dexamethasone test. " Control " group: * Lean or overweight patients (18 \< BMI \< 30 kg/m2), * Non cortisol secreting pituitary or adrenal tumor, * Patient in whom a biological evaluation of the HPA axis is recommended. " Hydrocortisone " group: * Lean or overweight patients (18 \< BMI \< 30 kg/m2), * Primary or secondary adrenal insufficiency, * With a need for hydrocortisone supplementation. Exclusion Criteria: * Patients with eating disorders, major depressive disorders or psychiatric disorders other than Cushing's syndrome, * Cannabis consumption, alcoholism or drug addiction, * Active smoking, * cortisone treatment other than hydrocortisone, * Pregnancy or feeding, * Surgery for obesity, * Incapability, * Pathology that is life-threatening in the short term, * Any situation that interfere with study or is risked for patient.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Adrenal insufficiency are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

adrenocortical insufficiency Cushing syndrome Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cushing's syndrome

Contacts and locations

Locations

  • Service d'Endocrinologie, Hopital Haut-Leveque

    Pessac, 33600, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.